摘要:
This invention concerns methods for determining whether an agent preferentially binds to at least one allelic variant of L-SIGN. The invention is also directed to agents that preferentially bind to at least one allelic variant of L-SIGN. The invention also provides methods and agents for treating and preventing disorders associated with infection by pathogens, including hepatitis C virus, that bind to particular L-SIGN allelic variants. The invention further provides methods for predicting the resistance or susceptibility of a subject to pathogen infection.
摘要:
This invention provides a first composition comprising a pharmaceutically acceptable particle and a stable HIV-1 pre-fusion envelope glycoprotein trimeric complex operably affixed thereto. This invention further provides a second composition comprising (a) a pharmaceutically acceptable particle, (b) an antigen, and (c) an agent which is operably affixed to the particle and is specifically bound to the antigen, whereby the antigen is operably bound to the particle. Finally, this invention provides related nucleic acids, vectors, cells, compositions, production methods, and prophylactic and therapeutic methods.
摘要:
This invention provides stable HIV-1 pre-fusion envelope glycoprotein trimeric complexes. This invention also provides related polypeptides and compositions comprising pharmaceutically acceptable particles and the trimeric complexes operably affixed thereto. This invention further provides related nucleic acids, vectors, host cells, compositions, production methods, and prophylactic and therapeutic methods.
摘要:
The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.
摘要:
This invention provides formulations of the anti-HIV therapeutic, CD4-IgG2, that contain higher concentrations of the therapeutic than were previously prepared, are stable, compatible with lyophilization, and safe to administer. These formulations are suitable for intravenous, subcutaneous and intramuscular delivery, the latter two routes being potentially useful for facilitating self-administration by HIV-infected individuals. This invention is also directed to methods of making the CD4-IgG2 formulations described in the disclosure, and methods of using the formulations to inhibit or prevent infect CD4+ cells from becoming infected with HIV, and to treat subjects having CD4+ cells infected with HIV.
摘要:
An optical sensor generates blood pressure data by obtaining two dimensional images of the surface of the patient's body, such as in the vicinity of the radial artery in the wrist area. Blood flow in the patient causes light to be reflected off a flexible reflective surface applied against the patient with a hold down pressure, and the scattering of light is sensed with a two-dimensional array of photo-detectors. The output of the photo-detectors during systolic and diastolic events is calibrated against known blood pressure measurements taken with a conventional air-cuff sphygmomanometer. Linear calibration relationships between output signal and blood pressure are obtained during calibration for some set of the photo-detectors. When blood pressure data is obtained from the patient, the linear calibration relationship between output signals and blood pressure is applied to the output signals from the set of photo-detectors, resulting in blood pressure data. The method provides for compensation for changes in hold down pressure and translation or rotation of the optical sensor relative to the patient. A preferred optical sensor arrangement for use in performing the method is also described.
摘要:
A patient support and environmental control apparatus comprises a frame and an upwardly-facing patient-support surface carried by the frame. An air curtain generator is mounted to the frame. The air curtain generator provides first and second curtains of air. The patient-support surface has a perimeter and the first and second curtains of air originate adjacent to the perimeter and converge at a point positioned to lie above the patient-support surface. The first and second curtains of air cooperate with the patient-support surface to define a patient space.
摘要:
An untucking resistant garment resists becoming untucked while being worn. The garment includes a garment body and an inner band of tacky material coupled to an inside surface of the garment body positioned proximate to a bottom opening of the garment body. An outer band of the tacky material is coupled to an outside surface of the garment body positioned proximate to the bottom opening.
摘要:
This invention provides a composition which comprises a monoclonal antibody or a fragment of such antibody, wherein the monoclonal antibody or fragment of such antibody binds to the same epitope as antibody PA14 produced by a hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) and a carrier. This invention also provides a method of treating a subject infected with HIV-1 which comprises administering to the subject an effective dose of the composition of the invention.
摘要:
The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO14O-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVgl:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmic designated pVgl:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
摘要翻译:本发明涉及抗CCR5抗体,其包含(i)两条轻链,每条轻链包含命名为pVK:HuPRO14O-VK(ATCC保藏号PTA-4097)的质粒的表达产物,和(ii)两条重链 每个重链包含称为pVgl:HuPRO140HG2-VH(ATCC保藏号PTA-4098)或质粒命名为pVgl:HuPRO140(mutB + D + I)-VH(ATCC保藏号PTA-4099)的质粒的表达产物 )或其与人细胞表面上的CCR5结合的片段。